Ela Borenstein
Angel Investor @ BDC Venture Capital
Montréal, Canada
Ela Borenstein is a Series B investor at BDC Venture Capital in Montréal focused on Biotechnology and Therapeutics. Ms. Ela Borenstein serves as Managing Partner at BDC Healthcare Venture. She joined BDC Venture Capital in 2007 and has over 20 years of management, entrepreneurial and consulting experience in the biopharmaceutical industry. She also serves on the Board of Thrasos Therapeutics. Prior to joining BDC, she was Chief Operating Officer at a VC-backedbiotech and previously held the position of Vice President in clinical, regulatory affairs and product strategy for various companies, as well as Senior Vice President of Scientific Affairs for Technilab Pharma during the company’s successful IPO. Her diversified background includes senior management responsibilities in drug and medical device development as well as key involvement in product acquisition and M&A activities. She is a Kauffman Fellow Class 17, a society for leaders in venture capital. Ela is an advisor and guest lecturer with several organizations and currently serves on the Board of Directors of Alethia Biotherapeutics and Milestone Pharma where she is active in their audit and compensation committees. She holds a Bachelor of Science in Chemistry from the University of Western Ontario, a Master of Science in Pharmacology from the University of Toronto and an MBA in Bio-Industries from Université du Québec à Montréal.
- Total investments:
- 7
- Last investment:
- Lead investor:
- 29%
Last updated:
For AI agents: llms.txt
Industries Ela Borenstein invests in
Stages Ela Borenstein invests in
Countries Ela Borenstein invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Biotechnology 5 (71%)
- Therapeutics 4 (57%)
- Health Care 3 (43%)
- Pharmaceutical 2 (29%)
- Medical Device 1 (14%)
Stage
- Series B 3 (43%)
- Seed 1 (14%)
- Series A 1 (14%)
- Series D 1 (14%)
- Funding Round 1 (14%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Milestone Pharmaceuticals is a drug development company developing novel small molecule therapeutics based on clinically validated mechanisms for cardiovascular diseases. Milestone's lead product is a novel and potent short-acting calcium channel antagonist for the systemic treatment of transient cardiovascular conditions such as atrialarrhythmias and angina. | $17M / Series B / Jun 15, 2015 | ||
| Thrasos is a bio-therapeutics company focused on the discovery and development of targeted therapies for the prevention and treatment of severe organ failure, with a principle focus on kidney disease. The Company's lead therapeutic program, THR-184, is focused on the prevention and treatment of acute kidney injury (AKI). The Company also has apreclinical development program for treating chronic kidney disease (CKD). | $21M / Series D / Mar 31, 2015 | ||
| Alethia BioTherapeutics, Inc., a biotechnology company, engages in the discovery and development of monoclonal antibody-based therapeutics focusing on the cancer-associated epithelial-to-mesenchymal transition, ovarian cancer, and on cancer-induced bone loss. Its products include Isogranulatimide, a G2 checkpoint inhibitor, which potentiates theresponse to several DNA-damaging chemotherapeutic agents; sCLU, a heterodimeric disulphide-linked glycoprotein of 449 amino acids, the over-expression of which is observed in various malignancies, including prostate, bladder, kidney, breast, colon, and lung tumors; AB-0447, an antigen that is expressed at the surface of ovarian cancer epithelial cells in greater than eighty five percent of malignant tumors; and AB-0440, a cell-surface protease-like protein, whose expression is stimulated early in osteoclast differentiation in response to RANK ligand. The company was founded in 2002 and is based in Montreal, Canada. | $4.7M / Series B / Nov 02, 2012 | ||
| Alethia BioTherapeutics, Inc., a biotechnology company, engages in the discovery and development of monoclonal antibody-based therapeutics focusing on the cancer-associated epithelial-to-mesenchymal transition, ovarian cancer, and on cancer-induced bone loss. Its products include Isogranulatimide, a G2 checkpoint inhibitor, which potentiates theresponse to several DNA-damaging chemotherapeutic agents; sCLU, a heterodimeric disulphide-linked glycoprotein of 449 amino acids, the over-expression of which is observed in various malignancies, including prostate, bladder, kidney, breast, colon, and lung tumors; AB-0447, an antigen that is expressed at the surface of ovarian cancer epithelial cells in greater than eighty five percent of malignant tumors; and AB-0440, a cell-surface protease-like protein, whose expression is stimulated early in osteoclast differentiation in response to RANK ligand. The company was founded in 2002 and is based in Montreal, Canada. | $9.2M / Series A / Sep 07, 2010 | ||
| Alethia BioTherapeutics, Inc., a biotechnology company, engages in the discovery and development of monoclonal antibody-based therapeutics focusing on the cancer-associated epithelial-to-mesenchymal transition, ovarian cancer, and on cancer-induced bone loss. Its products include Isogranulatimide, a G2 checkpoint inhibitor, which potentiates theresponse to several DNA-damaging chemotherapeutic agents; sCLU, a heterodimeric disulphide-linked glycoprotein of 449 amino acids, the over-expression of which is observed in various malignancies, including prostate, bladder, kidney, breast, colon, and lung tumors; AB-0447, an antigen that is expressed at the surface of ovarian cancer epithelial cells in greater than eighty five percent of malignant tumors; and AB-0440, a cell-surface protease-like protein, whose expression is stimulated early in osteoclast differentiation in response to RANK ligand. The company was founded in 2002 and is based in Montreal, Canada. | Seed | ||
| Cytochroma is a clinical stage specialty pharmaceutical company that designs, develops and commercializes prescription products to treat and prevent the clinical consequences of vitamin D insufficiency and secondary hyperparathyroidism (SHPT) associated with chronic kidney disease (CKD). The Company has an advanced portfolio of new therapiesdesigned to safely and effectively treat patients with vitamin D insufficiency and SHPT associated with Stage 3, 4 or 5 CKD. In addition, Cytochroma is developing novel therapies to treat elevated blood phosphorus levels (hyperphosphatemia) in order to improve the control of SHPT in CKD patients. | Series B | ||
| Gemin X Pharmaceuticals is dedicated to the discovery, development and commercialization of novel, targeted cancer therapeutics to improve the lives of patients.Gemin X's research on the Bcl-2 cell death regulation pathway has led to the discovery of GX15-070 (obatoclax), a novel small molecule that selectively reinitiates programmed celldeath, or apoptosis, and may also be effective in inducing cancer cell self-digestion, or autophagy. Obatoclax has shown promising activity in both preclinical and early human clinical studies and is currently in Phase 2 clinical trials as both a single agent and combination therapy. Obatoclax has patent protection through 2025. |
Co-Investors
About BDC Venture Capital
BDC Venture Capital is a major venture capital investor in Canada, active at every stage of the company's development cycle, from seed through expansion, with a focus on technology-based businesses that have high growth potential and that are positioned to become dominant players in their markets. The company helps create and develop strongCanadian businesses through financing, consulting services and securitization, with a focus on small and medium-sized enterprises.BDC Venture Capital has been involved in venture capital since 1975 and has to date invested in more than 400 companies involved in the areas of Life Sciences, Telecommunications, Information Technology and Advanced Technologies.
BDC Venture Capital Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Ajay Gopal
Associate Director
|
|||
Matt Stanley
Director, Cleantech Practice
|
|||
Annie Marsolais
Chief Marketing Officer
|
|||
Charles Lespérance
Partner
|
|||
Claude Miron
Managing Partner - Growth Equity Partners
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Ela Borenstein invest in?
Ela Borenstein invests primarily in Biotechnology, Therapeutics and Health Care startups, most often at Series B and Seed stage. Most of the 7 investments tracked by Shizune back companies in Canada. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Ela Borenstein?
Public channels for Ela Borenstein include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Ela Borenstein last invest?
The most recent investment recorded for Ela Borenstein closed in Jun 2015. Shizune tracks 7 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Sep 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
